← Browse by Condition
Medical Condition
neoadjuvant chemoimmunotherapy
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 2
NCT06056336 Phase 2
Recruiting
Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma
Enrollment
73 pts
Location
China
Sponsor
Guo Xufeng
NCT06289062 Phase 2
Recruiting
Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer
Enrollment
40 pts
Location
China
Sponsor
Tongji Hospital